Myelofibrosis is a serious bone marrow disorder that disrupts your body's normal production of blood cells. The result is extensive scarring in your bone marrow, leading to severe anemia, weakness, fatigue, and often, an enlarged spleen and liver. Myelofibrosis is an uncommon type of chronic leukemia — a cancer that affects the blood-forming tissues in the body. Myelofibrosis belongs to a group of diseases called myeloproliferative disorders.
Myelofibrosis is characterized by splenomegaly and debilitating constitutional symptoms that negatively impact patients' quality of life. ROBUST, a UK, open-label, phase II study, evaluated the safety and efficacy of ruxolitinib in patients with myelofibrosis (N = 48), including intermediate-1 risk patients.This was the first time that efficacy of ruxolitinib in myelofibrosis has been evaluated based on these criteria and the first time the MF-SAF was used in a population of patients solely from the United Kingdom.
In the past, the treatment of myelofibrosis has depended on the symptoms and degree of the low blood counts. A long-term remission is possible for some patients with bone marrow transplantation. Such treatment should be considered for younger patients and some others. Other treatment may involve:Blood transfusions and medicines to correct anemia, Radiation and chemotherapy, Medicines to target a genetic mutation, Splenectomy if swelling causes symptoms, or to help with anemia.